A Description of Signals During the First 18 Months of the EMA Pharmacovigilance Risk Assessment Committee

Drug Safety

Volumn 37, Issue 12, 2014, Pages 1059-1066

  Pacurariu, Alexandra C ^a,b   Coloma, Preciosa M ^a   van Haren, Anja ^b   Genov, Georgy ^c   Sturkenboom, Miriam C J M ^a   Straus, Sabine M J M ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b MEDICINES EVALUATION BOARD   (Netherlands)

^c EUROPEAN MEDICINES AGENCY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL TRIAL (TOPIC); DRUG LEGISLATION; DRUG MARKETING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EUROPEAN MEDICINES AGENCY; HEART DISEASE; HUMAN; IMMUNOPATHOLOGY; NEUROLOGIC DISEASE; RISK ASSESSMENT; SKIN DISEASE; DECISION MAKING; EUROPEAN UNION; LEGISLATION AND JURISPRUDENCE; POSTMARKETING SURVEILLANCE; PUBLIC HEALTH; RISK MANAGEMENT; TIME FACTOR;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DECISION MAKING; EUROPEAN UNION; HUMANS; PHARMACOVIGILANCE; PRODUCT SURVEILLANCE, POSTMARKETING; PUBLIC HEALTH; RISK ASSESSMENT; RISK MANAGEMENT; TIME FACTORS;

EID: 84912533810     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-014-0240-1     Document Type: Article

References (22)

1. Amery WK, ISPE. Why there is a need for pharmacovigilance. Pharmacoepidemiol Drug Saf. 1999;8:61–4.
2. Vandenbroucke JP. Observational research, randomised trials, and two views of medical science. PLoS Med. 2008;5:e67.
3. Stricker BHC, Psaty BM. Detection, verification, and quantification of adverse drug reactions. BMJ. 2004;329:44–7.
4. CIOMS Working Group. Practical aspects of signal detection in pharmacovigilance. Geneva; 2010.
5. EMA. Guideline on good pharmacovigilance practices, Module IX: signal management. 2012.
6. Commission Implementing Regulation (EU) No 520/2012. 2012.
7. Directive 2010/84/EU of the European Parliament and of the Council (Internet). (cited 2014 Apr 5). http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:348:0074:0099:EN:PDF.
8. Countdown to July 2012: the establishment and functioning of the PRAC, EMA/315258/2012 (Internet). (cited 2014 Apr 15). http://www.ema.europa.eu/docs/en_GB/document_library/Other/2012/07/WC500129301.pdf.
9. Arlett P, Portier G, de Lisa R, Blake K, Wathion N, Dogne JM, Spooner A, Raine J, Rasi G. Proactively managing the risk of marketed drugs: experience with the EMA Pharmacovigilance Risk Assessment Committee. Nat Rev Drug Discov. 2014;13:395–7.
10. PRAC meeting minutes (Internet). (cited 2014 Apr 15). http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/document_listing/document_listing_000353.jsp&mid=WC0b01ac05805a21cf.
11. PRAC recommendations on safety signals (Internet). (cited 2014 Apr 15). http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000375.jsp.
12. MedDRA. Introductory guide MedDRA version 15.1, MSSO-DI-6003-15.1.0. 2012.
13. Ishiguro C, Hall M, Neyarapally GA, Dal Pan G. Post-market drug safety evidence sources: an analysis of FDA drug safety communications. Pharmacoepidemiol Drug Saf. 2012;21:1134–6.
14. Pontes H, Clément M, Rollason V. Safety signal detection: the relevance of literature review. Drug Saf. 2014;37:471–9.
15. Moore TJ, Singh S, Furberg CD. The FDA and new safety warnings. Arch Intern Med. 2012;172:78–80.
16. Lester J, Neyarapally GA, Lipowski E, Graham CF, Hall M, Dal Pan G. Evaluation of FDA safety-related drug label changes in 2010. Pharmacoepidemiol Drug Saf. 2013;22:302–5.
17. Giezen TJ, Mantel-Teeuwisse AK, Straus SMJM, Schellekens H, Leufkens HGM, Egberts ACG. Safety-related regulatory actions for biologicals approved in the United States and the European Union. JAMA. 2008;300:1887–96.
18. Ciszkowski C, Madadi P, Phillips MS, Lauwers AE, Koren G. Codeine, ultrarapid-metabolism genotype, and postoperative death. N Engl J Med. 2009;361:827–8.
19. Mol PGM, Arnardottir AH, Motola D, Vrijlandt PJ, Duijnhoven RG, Haaijer-Ruskamp FM, et al. Post-approval safety issues with innovative drugs: a European cohort study. Drug Saf Int J Med Toxicol Drug Exp. 2013;36:1105–15.
20. Powers A, Cook G. Potential safety signals and their significance. Arch Intern Med. 2012;172:72–3.
21. Hochberg AM, Reisinger SJ, Pearson RK, O’Hara DJ, Hall K. Using data mining to predict safety actions from FDA adverse event reporting system data. Drug Inf J. 2007;41:633–43.
22. Edwards IR. Good pharmacovigilance practice and the curate’s egg. Drug Saf Int J Med Toxicol Drug Exp. 2012;35:429–35.